TransMedics Group (NASDAQ:TMDX) Stock Rating Lowered by Wall Street Zen

TransMedics Group (NASDAQ:TMDX) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other research firms have also recently weighed in on TMDX. Oppenheimer raised their price objective on TransMedics Group from $150.00 to $175.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Piper Sandler raised their price target on TransMedics Group from $140.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Needham & Company LLC boosted their price target on TransMedics Group from $166.00 to $174.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Morgan Stanley upped their price objective on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a report on Tuesday, December 2nd. Finally, Canaccord Genuity Group lifted their target price on shares of TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Six analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $150.67.

TransMedics Group Price Performance

Shares of TMDX opened at $145.26 on Friday. The company has a 50 day moving average of $133.80 and a two-hundred day moving average of $126.37. The company has a quick ratio of 6.59, a current ratio of 7.14 and a debt-to-equity ratio of 1.06. TransMedics Group has a twelve month low of $62.07 and a twelve month high of $156.00. The company has a market cap of $4.98 billion, a price-to-earnings ratio of 29.64 and a beta of 1.98.

Insider Transactions at TransMedics Group

In related news, Director David Weill sold 5,000 shares of TransMedics Group stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total transaction of $693,200.00. Following the completion of the sale, the director owned 12,134 shares of the company’s stock, valued at $1,682,257.76. The trade was a 29.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Gerardo Hernandez sold 920 shares of the stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $139.62, for a total transaction of $128,450.40. Following the completion of the transaction, the chief financial officer owned 15,064 shares in the company, valued at approximately $2,103,235.68. This trade represents a 5.76% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Royal Bank of Canada lifted its position in TransMedics Group by 47.9% during the first quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock valued at $1,788,000 after purchasing an additional 8,604 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of TransMedics Group by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock valued at $1,314,000 after buying an additional 868 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of TransMedics Group by 20.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock valued at $34,145,000 after buying an additional 86,721 shares during the period. AlphaQuest LLC boosted its stake in shares of TransMedics Group by 51.4% in the second quarter. AlphaQuest LLC now owns 1,950 shares of the company’s stock worth $261,000 after buying an additional 662 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its holdings in TransMedics Group by 12.6% during the second quarter. Envestnet Asset Management Inc. now owns 26,298 shares of the company’s stock worth $3,524,000 after acquiring an additional 2,933 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.